ReviewStem cells (Dayton, Ohio)2016
Concise Review: Mechanisms Behind Apoptotic Cell-Based Therapies Against Transplant Rejection and Graft versus Host Disease.
Review in Stem cells (Dayton, Ohio), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Silicone cryogel skeletons enhance the survival and mechanical integrity of hydrogel-encapsulated cell therapies.Science advances · 2024Article
- Secondary Lymphoid Organs in Mesenchymal Stromal Cell Therapy: More Than Just a Filter.Frontiers in immunology · 2022Review
- Impact of Cryopreservation and Freeze-Thawing on Therapeutic Properties of Mesenchymal Stromal/Stem Cells and Other Common Cellular Therapeutics.Current stem cell reports · 2022Review
- CD11cClinical and experimental immunology · 2021Article
- The Progress of Stem Cell Technology for Skeletal Regeneration.International journal of molecular sciences · 2021Review
- Apoptotic Donor Cells in Transplantation.Frontiers in immunology · 2021Review
- Donor myeloid derived suppressor cells (MDSCs) prolong allogeneic cardiac graft survival through programming of recipient myeloid cells in vivo.Scientific reports · 2020Article
- Article
- Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers.Frontiers in immunology · 2020Review
- Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD).Frontiers in immunology · 2020Review
- Innate Functions of Dendritic Cell Subsets in Cardiac Allograft Tolerance.Frontiers in immunology · 2020Review
- Pathogen reduction with riboflavin and ultraviolet light induces a quasi-apoptotic state in blood leukocytes.Transfusion · 2019Article
- Receptor tyrosine kinase MerTK suppresses an allogenic type I IFN response to promote transplant tolerance.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019Article
- Acute and chronic phagocyte determinants of cardiac allograft vasculopathy.Seminars in immunopathology · 2018Review
- TIGITNature communications · 2018Article
- Harnessing Apoptotic Cells for Transplantation Tolerance: Current Status and Future Perspectives.Current transplantation reports · 2017Article
- Differential Role of B Cells and IL-17 Versus IFN-γ During Early and Late Rejection of Pig Islet Xenografts in Mice.Transplantation · 2017Article
- Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease.Biomedicines · 2017Review
- The many ways tissue phagocytes respond to dying cells.Immunological reviews · 2017Review
- Tolerogenic interactions between CD8Blood · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The main limitations to the success of transplantation are the antigraft response developed by the recipient immune system, and the adverse side effects of chronic immunosuppression. Graft-versus-host disease (GVHD) triggered by donor-derived T lymphocytes against the recipient tissues is another serious obstacle in the field of hematopoietic stem cell transplantation. Several laboratories have tested the possibility of promoting antigen (Ag)-specific tolerance for therapy of graft rejection, GVHD, and autoimmune disorders, by developing methodologies that mimic the mechanisms by which the immune system maintains peripheral tolerance in the steady state. It has been long recognized that the silent clearance of cells undergoing apoptosis exerts potent immune-regulatory effects and provides apoptotic cell-derived Ags to those Ag-presenting cells (APCs) that internalize them, in particular macrophages and dendritic cells. Therefore, in situ-targeting of recipient APCs by systemic administration of leukocytes in early apoptosis and bearing donor Ags represents a relatively simple approach to control the antidonor response against allografts. Here, we review the mechanisms by which apoptotic cells are silently cleared by phagocytes, and how such phenomenon leads to down-regulation of the innate and adaptive immunity. We discuss the evolution of apoptotic cell-based therapies from murine models of organ/tissue transplantation and GVHD, to clinical trials. We make emphasis on potential limitations and areas of concern of apoptotic cell-based therapies, and on how other immune-suppressive therapies used in the clinics or tested experimentally likely also function through the silent clearance of apoptotic cells by the immune system. Stem Cells 2016;34:1142-1150.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.